Shopping Cart
- Remove All
![TargetMol](https://newstatic.targetmol.com/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $82 | Backorder | |
10 mg | $117 | Backorder | |
25 mg | $232 | Backorder | |
50 mg | Inquiry | Backorder | |
100 mg | Inquiry | Backorder |
Description | LSKL, Inhibitor of Thrombospondin (TSP-1) TFA, a latency-associated protein (LAP)-TGFβ derived tetrapeptide, is a competitive antagonist of TGF-β1. |
In vitro | The KTFR sequence from ADAMTS1 is responsible for the interaction with the LSKL, Inhibitor of Thrombospondin (TSP-1) (LSKL peptide) from the latent form of TGF-β, leading to its activation [2]. |
In vivo | LSKL, Inhibitor of Thrombospondin (TSP-1) (1 mg/kg; i.p.; male Sprague-Dawley rats) is protective against subarachnoid fibrosis, attenuates ventriculomegaly and effectively suppresses hydrocephalus. LSKL, Inhibitor of Thrombospondin (TSP-1) treatment inhibits TGF-β1 activity and subsequent Smad2/3 signaling [1]. LSKL, Inhibitor of Thrombospondin (TSP-1) (30 mg/kg, i.p.) successfully inhibits TGF β-Smad signal activation induced by partial hepatectomy. It successfully attenuates TGF-β-Smad signal activation by antagonizing TSP-1, but not by reducing TSP-1 protein expression. LSKL, Inhibitor of Thrombospondin (TSP-1) accelerates hepatocyte proliferation after hepatectomy [3]. |
Molecular Weight | 572.62 |
Formula | C23H43F3N6O7 |
Cas No. |
Storage | keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.